1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Motherisk Update 2014
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting,
Details to be announced
- Read more in our News Archive
Current Studies at Motherisk
Neurodevelopment of Children Exposed in-Utero to Chemotherapy for Maternal Breast Cancer (Dr. I Nulman)
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Motherisk News: Pregnant women shouldn't fear taking antidepressant drugs
Researchers have found taking antidepressants during pregnancy does not increase the chance of birth defects
TORONTO (March 31, 2009) - Taking an antidepressant during pregnancy has become a difficult and complicated process, mostly because of the conflicting information regarding safety. Researchers at The Hospital for Sick Children?s (SickKids) Motherisk Program studied the link between antidepressants and birth defects. The research will be published in the April edition of The Canadian Journal of Psychiatry.
The SickKids Motherisk Program is a clinical research and teaching program which provides evidence-based information and guidance about the safety or risk to the developing fetus or infant, as a result of maternal exposure to drugs, chemicals, diseases, radiation or environmental agents. In this study, the researchers followed up on pregnant women, who called Motherisk and who had taken antidepressants prior to becoming pregnant, through to the first three months of pregnancy. The researchers investigated whether or not the babies had birth defects.
The scientists contacted 1,243 women and completed pregnancy outcomes. Out of these women, 928 had taken the antidepressant in the first trimester and delivered a live born infant. Collectively, the women had taken 11 different antidepressants: bupropion (113), citalopram (184), escitalopram(21), fluvoxamine(52) nefazodone(49), paroxetine(148), mirtazepine(68), fluoxetine(61), trazodone(17) venlafaxine(154), sertraline(61).
The rates of birth defects were compared to another group of 928 women, who were not exposed to antidepressants during pregnancy. The incidence of birth defects was similar in both groups, which was within the baseline of one to three per cent expected in the population. The researchers concluded the use of antidepressants in the first trimester of pregnancy is not associated with an increased risk birth defects. In addition, no individual antidepressant was associated with an increased risk of a specific malformation.
"We hope this information reassures pregnant women who require pharmacological treatment for depression, as well as their physicians who are faced with the complicated and sometimes difficult decision of whether to prescribe an antidepressant to a pregnant woman," says Adrienne Einarson, Assistant Director of The Motherisk Program at SickKids and lead author of the paper.